ArticlePoultry science2026
Structurally distinct yeast-derived β-glucans modulate intestinal morphology and microbial metabolism in broiler chickens differentially.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the effects of yeast β-glucan structural properties on broiler growth performance, intestinal morphology, caecal metabolite profiles, and microbial composition. A total of 952 one-day-old Ross 308 broilers were allocated to a 38-day trial that included a maize-based basal diet (CON) and six basal diets supplemented with three structurally distinct, high-purity yeast β-glucans: SLG (water-soluble, low molecular weight [MW]), IMG (water-insoluble, medium MW), and IHG (water-insoluble, high MW). Each β-glucan was supplemented at two inclusion levels (0.02 % [L] and 0.35 % [H]). Compared with the CON group, IHG_L supplementation improved body-weight uniformity and enhanced ileal villus height (VH) and VH/crypt depth (CD) ratio (p < 0.05), while SLG_L increased jejunal VH (p < 0.05). SLG_H supplementation increased caecal propionate concentration on day 10 and elevated SCFA levels and the SCFA/BCFA ratio on day 38, accompanied by an increase in the Berger Parker index (p < 0.05). Across β-glucan structures, IHG supplementation showed higher levels of ileal VH and VH/CD ratio relative to both SLG and IMG (p < 0.05). Additionally, IHG reduced the Berger-Parker index compared with SLG, while enhancing the Shannon index relative to both SLG and IMG (p < 0.01). Regarding dosage effects, the high dose significantly increased propionate production on day 10 and elevated butyrate, total SCFAs, and the SCFA/BCFA ratio while reducing BCFA concentrations compared with the low dose on day 38 (p < 0.05). Distinct structure- and dose-dependent alterations in microbial community composition were also observed, and these compositional changes were closely linked to metabolite profiles and intestinal morphology. Overall, these findings underscore an integrated host-microbiota-metabolite response framework that is jointly modulated by β-glucan structural characteristics and dosage in broilers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.